Choose your font:
 Arimo
 Merriweather
 Mukta Malar
 Open Sans Condensed
 Rokkitt
 Source Sans Pro
 Login


 English 
 Français 
 Português 
 Español 

[Valid RSS] RSS
bar

Database - (CIANE)

Description of this bibliographical database (CIANE website)
Currently 3111 records
YouTube channel (tutorial)

https://ciane.net/id=3051

Created on : 10 Jan 2019
Modified on : 10 Jan 2019

 Modify this record
Do not follow this link unless you know an editor’s password!


Share: Facebook logo   Tweeter logo   Hard

Bibliographical entry (without author) :

Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes. N Engl J Med 2013; 368:814-823

Author(s) :

Björn Pasternak, Henrik Svanström and Anders Hviid

Year of publication :

2013

URL(s) :

https://www.nejm.org/doi/full/10.1056/NEJMoa121103…
https://doi.org/10.1056/NEJMoa1211035

Résumé (français)  :

Abstract (English)  :

Background

Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied.

Methods

We investigated the risk of adverse fetal outcomes associated with ondansetron administered during pregnancy. From a historical cohort of 608,385 pregnancies in Denmark, women who were exposed to ondansetron and those who were not exposed were included, in a 1: 4 ratio, in propensity-score–matched analyses of spontaneous abortion (1849 exposed women vs. 7396 unexposed women), stillbirth (1915 vs. 7660), any major birth defect (1233 vs. 4932), preterm delivery (1792 vs. 7168), and birth of infants at low birth weight and small for gestational age (1784 vs. 7136). In addition, estimates were adjusted for hospitalization for nausea and vomiting during pregnancy (as a proxy for severity) and the use of other antiemetics.

Results

Receipt of ondansetron was not associated with a significantly increased risk of spontaneous abortion, which occurred in 1.1% of exposed women and 3.7% of unexposed women during gestational weeks 7 to 12 (hazard ratio, 0.49; 95% confidence interval [CI] , 0.27 to 0.91) and in 1.0% and 2.1%, respectively, during weeks 13 to 22 (hazard ratio, 0.60; 95% CI, 0.29 to 1.21). Ondansetron also conferred no significantly increased risk of stillbirth (0.3% for exposed women and 0.4% for unexposed women; hazard ratio, 0.42; 95% CI, 0.10 to 1.73), any major birth defect (2.9% and 2.9%, respectively; prevalence odds ratio, 1.12; 95% CI, 0.69 to 1.82), preterm delivery (6.2% and 5.2%; prevalence odds ratio, 0.90; 95% CI, 0.66 to 1.25), delivery of a low-birth-weight infant (4.1% and 3.7%; prevalence odds ratio, 0.76; 95% CI, 0.51 to 1.13), or delivery of a small-for-gestational-age infant (10.4% and 9.2%; prevalence odds ratio, 1.13; 95% CI, 0.89 to 1.44).

Conclusions

Ondansetron taken during pregnancy was not associated with a significantly increased risk of adverse fetal outcomes. (Funded by the Danish Medical Research Council.)

Sumário (português)  :

Resumen (español)  :

Full text (public) :

Comments :

Argument (français) :

L’ondansétron pris pendant la grossesse n’a pas été associé à une augmentation significative du risque d’effets indésirables chez le fœtus.

Argument (English):

Ondansetron taken during pregnancy was not associated with a significantly increased risk of adverse fetal outcomes.

Argumento (português):

O ondansetron tomado durante a gravidez não foi associado a um risco significativamente aumentado de resultados fetais adversos.

Argumento (español):

Keywords :

➡ premature baby ; iatrogeny ; maternal health ; baby’s health ; low birth weight ; cot death ; miscarriage

Author of this record :

Bernard Bel — 10 Jan 2019

Discussion (display only in English)
 
➡ Only identified users



 I have read the guidelines of discussions and I accept all terms
[Hide guidelines]

➡ Discussion guidelines

1) Comments aim at clarifying the content of the publication or suggesting links for a better comprehension of its topic
2) All comments are public and opinions expressed belong to their authors
3) Avoid casual talk and personal stories
4) Any off-topic comment or containing inappropriate statements will be deleted without notice

barre

New expert query --- New simple query

Creating new record --- Importing records

User management --- Dump database --- Contact

bar

This database created by Alliance francophone pour l'accouchement respecté (AFAR) is managed
by Collectif interassociatif autour de la naissance (CIANE, https://ciane.net).
It is fed by the voluntary contributions of persons interested in the sharing of scientific data.
If you agree with this project, you can support us in several ways:
(1) contributing to this database if you have a minimum training in documentation
(2) or financially supporting CIANE (see below)
(3) or joining any society affiliated with CIANE.
Sign in or create an account to follow changes or become an editor.
Contact bibli(arobase)ciane.net for more information.

Valid CSS! Valid HTML!
Donating to CIANE (click “Faire un don”) will help us to maintain and develop sites and public
databases towards the support of parents and caregivers’ informed decisions with respect to childbirth